Circulating levels of several myokines will be measured in serum samples obtained from women in various categories of bone density and according to the presence of fracture or not as well as before and after treatment with teriparatide and denosumab
Serum samples for the measurement of several myokines will be obtained from: 1) equal groups of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with osteoporosis; 2) women with hip fracture compared with controls (women subjected to surgery due to knee osteoathritis); 3) women with osteoporosis treated with teriparatide or denosumab for 12 months
Study Type
OBSERVATIONAL
Enrollment
220
1 subcutaneous injection daily for 12 months
1 subcutaneous injection every 6 months for 12 months
424 General Military Hospital
Thessaloniki, Northern Greece, Greece
follistatin
circulating levels of myokine follistatin at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
activin-A
circulating levels of myokine activin-A at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
FSTL3
circulating levels of myokine FSTL3 at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
activin-B
circulating levels of activin-B at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
irisin
circulating levels of myokine irisin at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.